102625-64-9

Basic information

• Product Name: 5-Difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]thio}-1H-benzimidazole
• Synonyms: Pantoprazole Related Compound B (25 mg) (5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole);Pantoprazole Thioether;5-(DifluoroMethoxy)-2-(((3,4-diMethoxypyridin-2-yl)Methyl)thio)-1H-benzo[d]iMidazole;Pantoprazole EP IMpurity-B (USP RC B);5-DIFLUOROMETHOXY-2-[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]THIO-1H-BENZIMIDAZOLE PANTOPRAZOLE SULFIDE;Pantoprazole EP IMpurity B;5-DifluoroMethoxy-2-[(3,4-diMethoxy-2-pyridyl)Methyl]thio-1H-benziMidazole, 95%;Pantoprazole Sulfide (Pantoprazole IMpurity B)
• CAS NO: 102625-64-9
• Molecular Formula: C₁₆H₁₅F₂N₃O₃S
• Molecular Weight: 367.37
• EINECS: 1806241-263-5
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;(intermediate of pantoprazole);Various Metabolites and Impurities;Metabolites;Pantoprazole Sodium
• Mol File: 102625-64-9.mol
• Article Data: 23

Chemical Properties

• Melting Point: 110-118°C
• Boiling Point: 526.293 °C at 760 mmHg
• Flash Point: 272.1 °C
• Appearance: beige solid
• Density: 1.43 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 8.97±0.10(Predicted)
• BRN: 5358607
• CAS DataBase Reference: 5-Difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]thio}-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]thio}-1H-benzimidazole(102625-64-9)
• EPA Substance Registry System: 5-Difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]thio}-1H-benzimidazole(102625-64-9)

Safety Data

• Hazardous Substances Data: 102625-64-9(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

Different sources of media describe the Uses of 102625-64-9 differently. You can refer to the following data:
1. A metabolite of Pantoprazole, an antiulcerative, gastric pump inhibitor
2. A metabolite of Pantoprazole (P183000), an antiulcerative, gastric pump inhibitor.
3. Pantoprazole Sulfide (Pantoprazole EP Impurity B) is a metabolite of Pantoprazole (P183000), an antiulcerative, gastric pump inhibitor.

InChI:InChI=1/C16H15F2N3O3S/c1-22-13-5-6-19-12(14(13)23-2)8-25-16-20-10-4-3-9(24-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

Upstream product

• 97963-62-7 5-(difluoromethoxy)-2-mercapto-1H-benzimidazole 
• 72830-09-2 2-Chloromethyl-3,4-dimethoxy-pyridine; hydrochloride 
• 169905-10-6 2-(chloromethyl)-3,4-dimethoxypyridine 
• 172282-50-7 4-(difluoromethoxy)benzene-1,2-diamine 
• 107512-34-5 4-Chloro-3-methoxy-2-methyl-pyridine 
• 577-71-9 3,4-dinitophenol 
• 86604-75-3 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride 
• 102625-99-0 2-acetoxymethyl-3,4-dimethoxypyridine 
• 72830-07-0 3,4-dimethoxy-2-methylpyridine N-oxide ? 
• 72830-08-1 2-hydroxymethyl-3,4-dimethoxypyridine 
• 122307-41-9 4-chloro-3-methoxy-2-methylpyridine N-oxide 
• 35392-65-5 3-methoxy-2-methylpyridine 1-oxide 
• 76015-11-7 3-methoxy-2-methylpyridin-4(1H)-one 
• 15931-25-6 3-methoxy-2-methyl-4-nitropyridine 1-oxide 

Downstream Products

• 142678-35-1 5‐(difluoromethoxy)‐2‐[(3,4‐dimethoxy‐2‐pyridyl)methylsulfinyl]‐1H‐benzimidazole 
• 102625-70-7 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole 
• 142706-18-1 ((R)-6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole) 
• 953787-55-8 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl-1-oxide)methylsulfonyl]-1H-benzoimidazole 
• 138786-67-1 pantoprazole sodium 

Relevant articles and documents

An improved and single-pot process for the production of pantoprazole substantially free from sulfone impurity

Pantoprazole (1), a substituted benzimidazole derivative, is an irreversible proton pump inhibitor, essentially used for the prevention and treatment of gastric acid-related diseases. The process for its preparation generally suffers from the drawback of producing a potential sulfone impurity (5). The present work details a report of the journey towards the development of a simple, single-pot process for the production of pantoprazole, substantially free from sulfone impurity (5). The detailed study of the different parameters affecting the purity and yield of the compound has been presented.

An electronic circular dichroism study for the structurechiroptical relationship of chiral proton pump inhibitors

In this paper, we investigated the electronic circular dichroism (ECD) of proton pump inhibitors (PPIs) using a method of combining experimental spectrum and time-dependent density functional theory (TD-DFT) calculations. In our research, an intriguing helicity-like phenomenon was discovered for the relationship between static dipole moment and ECD curves of different conformers in lansoprazole. The scope and validity of the precious phenomenon have been examined by four PPIs using the same method. Hence, it can be used as a reference to determine and verify the absolute configuration of PPIs-type and PPIs-like chiral sulfoxide.

A pantoprazole sodium production process (by machine translation)

Pantoprazole sodium (Pantoprazole Sodium), chemical name 5 - difluoro - 2 - [[ (3, 4 - dimethoxy - 2 - pyridyl) - methyl] sulfinyl] - 1 H - benzimidazole sodium monohydrate, is the treatment of peptic ulcer and acute gastric mucosal lesion caused by bleeding of a safe, effective drug, to peptic ulcer and reflux esophagitis have very high cure rate. For the injection of the injection by the German hectogram (Byk Gulden) the pharmaceutical Company (now renamed Takeda pharmaceutical companies) lead to the successful development of, for 1994 years 10 months in south Africa listed for the first time, tradenames for pan tuo lOOc. The present invention provides a pantoprazole sodium production process. A specific process comprises the following process: 1, pantoprazole sodium intermediate synthesis of IV; 2, pantoprazole sodium crude synthesis of V; 3, crude refined product. (by machine translation)

A method for preparing divides the request to pull zuozuo the sodium nitrogen oxide impurity

The present invention discloses a preparation method for a pantoprazole sodium oxynitride impurity. The preparation method comprises the following steps: 2-chloromethyl-3,4-dimethoxypyridine hydrochloride is used as a raw material to react with 5-difluoromethoxy-2-mercapto-1H-benzimidazole and produce 5-difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridyl)methyl]sulphur}-1H-benzimidazole; then in a presence of hydrogen peroxide and acetic acid, with copper hydroxyphosphate as a catalyst, oxidation is performed to obtain an oxynitride product of the pantoprazole; and finally a sodium salt is obtained by a reaction with sodium hydroxide, and pantoprazole sodium oxynitride impurity is obtained. According to the preparation method, no extreme reaction condition is needed, and raw materials are easy to obtain; the oxidant is capable of selective oxidations, which can not only oxidate pyridine ring, but also can oxidate thioether to sulfoxide, and by controlling the dosage of the catalyst, i.e., copper hydroxyphosphate, a peroxidation is less likely to occur (oxidate thioether to sulphone); and a post-treatment is simple and easy in operation, and the resulting product is high in purity and high in yield.